

Update from the NCI Acting Director

*Douglas R. Lowy
Acting Director, National Cancer Institute
National Institutes of Health*

Joint NCAB/BSA Meeting
June 20, 2017



NATIONAL CANCER INSTITUTE

Norman E. (Ned) Sharpless


- To be named NCI Director by the President

Warren Kibbe

- Acting Deputy Director, CBIIT Director
 - CBIIT = Center for Biomedical Informatics and Information Technology
- Moving to Duke in August
- New positions:
 - Chief for Translational Biomedical Informatics in the Department of Biostatistics and Bioinformatics, Duke University School of Medicine;
 - Chief Data Officer, Duke Cancer Institute



NCI APPROPRIATIONS 2013-2017 (in billions)



Doug Lowy & Tony Fauci with Senator Roy Blunt & Congressman Tom Cole (May 2, 2017)



Importance of Research Supported by NCI's Regular Appropriation (1)

- Largely non-overlapping with Cancer Moonshot research activities
- Some ongoing examples:
 - Training the next generation of investigators
 - Investigator-initiated research
 - Most clinical trials
 - PMI Oncology
 - RAS initiative

Importance of Research Supported by NCI's Regular Appropriation (2)

- Some new initiatives:
 - National Cryo-Electron Microscopy Facility, FNLCR
 - FNLCR = Frederick National Laboratory for Cancer Research
 - <https://www.cancer.gov/research/resources/cryoem>
 - TMIST breast cancer screening trial
 - TMIST = Tomosynthesis Mammographic Imaging Screening Trial

TMIST Breast Cancer Screening Trial

- Collaboration with ECOG-ACRIN
- Primary goal: Determine if ***cumulative rate of advanced breast cancer*** in women undergoing screening with ***tomosynthesis plus digital mammography*** is reduced compared to ***digital mammography alone***
- RCT, 165,000 women 45-74
- Menopausal normal risk: biennial screens: 0, 24, 48 months
- Menopausal increased risk: annual screens: 0, 12, 24, 36, 48 months
- Biorepository

One Dose HPV Vaccine Efficacy Trial: Moonshot

- Goal: Determine if a single HPV vaccine dose confer long-term protection in adolescent girls
- Four arm Non-inferiority RCT in Costa Rica: 1 & 2 doses Gardasil-9 (Merck), 1 & 2 doses Cervarix (GlaxoSmithKline)
- Primary end-point: reduction in persistent HPV16/18 cervical infection
- Collaboration between Gates Foundation and NCI; companion immunogenicity trials in USA & Tanzania; HPV serology standardization project
- Potential impact if results are positive: Increase HPV vaccine uptake, save money
- More info: Kreimer et al, JNCI 2015



NATIONAL CANCER INSTITUTE